Her Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029
Grail's Galleri cancer-detection test, priced at $949, is not covered by Medicare. FDA advisory panel supported its effectiveness, safety, and risk-benefit profile. Medicare coverage may start in 2029, but age restrictions could exclude some beneficiaries. Grail expects FDA decision by early Q1 2027. Promotional pricing and other coverage options may reduce out-of-pocket costs.
How this was made
The 30-second read
Why it matters
The panel vote is the first public endorsement of Galleri's clinical value, setting the stage for a potential regulatory milestone.
Market read
Grail's stock may react to the upcoming FDA decision; investors should monitor the approval timeline and Medicare coverage rules.
What to watch
Age‑based Medicare restrictions and the need for CMS coverage determination could dampen commercial upside.
Background
Grail's Galleri test is a multi-cancer early detection blood assay currently sold as a laboratory‑developed test. Medicare will not cover it until 2029, pending FDA approval and CMS coverage.
Ticker impact
FDA advisory panel voted favorably for Galleri's effectiveness and safety, with a decision expected by early Q1 2027.
potential upside if FDA approval is granted; current uncertainty may keep price muted.
Regulatory clearance is a key catalyst for Grail; the panel's vote is a primary new fact that can move the stock.
Market effects
Positive FDA outcome could spur broader interest in multi-cancer early detection tests across the biotech sector.
U.S. healthcare investors may re‑price related diagnostics companies.
Limited to U.S. and markets with similar regulatory pathways.
Counterpoint
Even with a favorable panel vote, the FDA could still reject the test, and Medicare coverage remains uncertain until 2029.
Key entities
- CompanyGrail
Developer of the Galleri multi-cancer early detection test.
- RegulatorFDA
U.S. Food and Drug Administration, reviewing Galleri for approval.
